Penney Test (300887.SZ) released first-half results, with a net loss of 101 million yuan to mother

According to the Zhitong Finance App, Penney Test (300887.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 569 million yuan, an increase of 0.81% over the previous year. Net loss attributable to shareholders of listed companies was 101 million yuan, and net loss of non-recurring profit and loss attributable to shareholders of listed companies was 109 million yuan.

In the first half of the year, on the CRO industry policy side, clinical trial review was reduced from 60 working days to 30 days, and clinical trials can be initiated within 12 weeks after IND is approved; the new GCP standard ICH E6 (R3) will be implemented in September, and international mutual recognition of clinical data will open up the path to overseas; the “818 New Deal” clarifies the full cell/gene/stem cell chain compliance path for the first time, directly boosting the service demand of pre-clinical CRO in the CGT field; the medical insurance and commercial insurance double catalogue shortens the repayment cycle for innovative drugs by 2-3 years, and companies are willing to invest more in R&D to lift out CRO pharmaceuticals Innovative drug CRO benefits The reverse scissor difference is formed simultaneously, which is conducive to the company's business expansion.

The pharmaceutical and medical device sector is also an important growth pole for the testing industry. New drug development has gone through all stages of clinical trials, and quality sampling after drug marketing also requires strict testing procedures to ensure the safety and efficacy of drugs. From testing raw materials to verifying the performance and safety of finished products, every step must follow high standards and specifications. As a result, a large number of testing requirements have arisen, driving the continuous development of the industry in the pharmaceutical field.